Search

everythinglearnresearchcommunity

for

Search:↓

Latanoprost can effectively treat eyelash hair loss, with 45% of patients showing hair regrowth and no reported side effects.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

DNCB helps regrow hair in alopecia areata patients, but safer alternatives are needed.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.

Topical corticosteroids are the best initial treatment for children's alopecia areata.

Alopecia areata patients have more Propionibacterium acnes and less Staphylococcus epidermidis on their scalps.

Gut health may influence Alopecia Areata, suggesting new treatments.

People with alopecia areata often have lower vitamin D levels and are more likely to be deficient in it.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Epigenetic changes in blood cells may contribute to alopecia areata.

Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.

Contact sensitizers like DCP and SADBE are the most effective treatments for alopecia areata.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

Monthly oral corticosteroid pulses effectively treat widespread alopecia areata in young patients.

Some treatments can help with hair regrowth in alopecia areata, but results vary and long-term use is often needed without changing the disease's outcome.

New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.

People with hair loss conditions experience more anxiety, depression, and a lower quality of life than those without these conditions.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

Vitiligo is not linked to coeliac disease, but a small number of alopecia areata patients may have it, suggesting they should be tested for coeliac disease.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

Combining 5% minoxidil and 0.5% anthralin can help regrow hair in some severe alopecia areata patients.

Using patients' own fat-derived cells to treat alopecia areata significantly improved hair growth and was safe.

Nail problems are common in people with alopecia areata, often leading to cosmetic and functional issues, but more research is needed for treatment guidelines.

Plasmacytoid dendritic cells are a key factor in causing hair loss in alopecia areata and could help differentiate it from other hair loss conditions.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

Sulfasalazine may help treat persistent alopecia areata.

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.